Milestone Pharmaceuticals (MIST) Projected to Post Earnings on Wednesday

Key Points

• Q1 2026 earnings set for May 13 (before market): Milestone will report results and host a call at 7:00 AM ET, with analysts forecasting $0.19 EPS and $30.115M in revenue.
• In the prior quarter Milestone posted a ($0.16) EPS that beat estimates but reported just $1.44M in revenue versus a $37.52M estimate, and analysts now expect roughly $0 EPS for the current fiscal year and about -$1 EPS next year, signaling near‑term revenue and profitability uncertainty.
• Shares opened at $1.88 (12‑month range $1.00–$3.06) with a market cap of ~$225M; the stock carries a consensus "Moderate Buy" rating and $7.50 average price target, while CEO Joseph Oliveto sold 36,500 shares under a Rule 10b5‑1 plan, reducing his stake by 7.56%.

Milestone Pharmaceuticals (NASDAQ:MIST - Get Free Report) is expected to release its Q1 2026 results before the market opens on Wednesday, May 13th. Analysts expect Milestone Pharmaceuticals to post earnings of $0.19 per share and revenue of $30.1150 million for the quarter. Interested persons may visit the the company's upcoming Q1 2026 earning results page for the latest details on the call scheduled for Wednesday, May 13, 2026 at 7:00 AM ET.

Milestone Pharmaceuticals (NASDAQ:MIST - Get Free Report) last issued its earnings results on Friday, March 20th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.18) by $0.02. The firm had revenue of $1.44 million during the quarter, compared to analyst estimates of $37.52 million. On average, analysts expect Milestone Pharmaceuticals to post $0 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Milestone Pharmaceuticals Price Performance

Shares of MIST opened at $1.88 on Wednesday. Milestone Pharmaceuticals has a 12-month low of $1.00 and a 12-month high of $3.06. The business has a 50-day simple moving average of $1.68 and a two-hundred day simple moving average of $1.93. The company has a quick ratio of 7.96, a current ratio of 8.01 and a debt-to-equity ratio of 1.37. The stock has a market cap of $224.92 million, a PE ratio of -2.38 and a beta of 1.04.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on MIST. Zacks Research cut Milestone Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Tuesday, February 24th. HC Wainwright reaffirmed a "buy" rating and set a $8.00 target price on shares of Milestone Pharmaceuticals in a report on Tuesday, January 6th. Wall Street Zen downgraded Milestone Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Saturday, April 11th. Finally, Raymond James Financial initiated coverage on Milestone Pharmaceuticals in a report on Friday, April 10th. They set a "strong-buy" rating and a $6.00 target price on the stock. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $7.50.

Insider Activity

In other news, CEO Joseph Oliveto sold 36,500 shares of the business's stock in a transaction dated Thursday, April 16th. The stock was sold at an average price of $2.26, for a total value of $82,490.00. Following the transaction, the chief executive officer directly owned 446,244 shares of the company's stock, valued at $1,008,511.44. The trade was a 7.56% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 19.50% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Invesco Ltd. acquired a new position in shares of Milestone Pharmaceuticals in the 4th quarter valued at about $44,000. Engineers Gate Manager LP acquired a new position in shares of Milestone Pharmaceuticals in the 4th quarter valued at about $119,000. ADAR1 Capital Management LLC acquired a new position in shares of Milestone Pharmaceuticals in the 4th quarter valued at about $202,000. Cetera Investment Advisers acquired a new position in shares of Milestone Pharmaceuticals in the 4th quarter valued at about $42,000. Finally, Guardian Wealth Advisors LLC NC lifted its stake in shares of Milestone Pharmaceuticals by 25.2% in the 4th quarter. Guardian Wealth Advisors LLC NC now owns 263,200 shares of the company's stock valued at $532,000 after purchasing an additional 53,000 shares during the period. 86.18% of the stock is owned by institutional investors and hedge funds.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for respiratory diseases. The company's research emphasizes both biologic and small-molecule approaches designed to improve mucociliary clearance, reduce airway inflammation and address chronic and refractory cough. Milestone's pipeline targets key underserved conditions such as cystic fibrosis, primary ciliary dyskinesia and severe asthma.

Milestone's lead product candidates are delivered through inhalation or systemic administration, reflecting the company's commitment to optimizing therapeutic delivery directly to the lungs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.